We considered intratumoral CD8+ TILs and tumor PD-L2 expression in combination, and we found that tumor PD-L2 status was not associated with 5-year OS in the subgroup of patients with high CD8+ TILs (CD8+ TILsH/PD-L2H: 69.7% vs CD8+ TILsH/PD-L2L: 57.1%, p = 0.167, Fig. 4B). This evidence concerns the gene PDCD1LG2 and neoplasm.